ABSTRACT
Decellularized extracellular matrix (ECM) biomaterials are increasingly used in regenerative medicine for abdominal tissue repair. Emerging ECM biomaterials with greater compliance target surgical procedures like breast and craniofacial reconstruction to enhance aesthetic outcome. Clinical studies report improved outcomes with newly designed ECM scaffolds, but their comparative biological characteristics have received less attention. In this study, we investigated scaffolds derived from dermis (AlloDerm Regenerative Tissue Matrix), small intestinal submucosa (Surgisis 4-layer Tissue Graft and OASIS Wound Matrix), and mesothelium (Meso BioMatrix Surgical Mesh and Veritas Collagen Matrix) and evaluated biological properties that modulate cellular responses and recruitment. An assay panel was utilized to assess the ECM scaffold effects upon cells. Results of the material-conditioned media study demonstrated Meso BioMatrix and OASIS best supported cell proliferation. Meso BioMatrix promoted the greatest migration and chemotaxis signaling, followed by Veritas and OASIS; OASIS had superior suppression of cell apoptosis. The direct adhesion assay indicated that AlloDerm, Meso BioMatrix, Surgisis, and Veritas had sidedness that affected cell-material interactions. In the chick chorioallantoic membrane assay, Meso BioMatrix and OASIS best supported cell infiltration. Among tested materials, Meso BioMatrix and OASIS demonstrated characteristics that facilitate scaffold incorporation, making them promising choices for many clinical applications. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 585-593, 2017.
Subject(s)
Cell Proliferation , Chemotaxis , Dermis/chemistry , Extracellular Matrix/chemistry , Fibroblasts/metabolism , Signal Transduction , Tissue Scaffolds/chemistry , Animals , Apoptosis , Cattle , Humans , Mice , NIH 3T3 Cells , SwineABSTRACT
KEY CLINICAL MESSAGE: An 18-year-old was presented with a large inflamed appendix (compressed by the instrument) and a spermatic cord with right undescended testicle (cryptorchidism). Patients who undergo orchiopexy after age 12 years, or no orchiopexy, are 2-6 times as likely to have testicular cancer as those who undergo prepubertal orchiopexy.
